SCYNEXIS, Inc.

SCYNEXIS develops medicines for difficult-to-treat infections in the US. Its lead product candidate is Ibrexafungerp for invasive candidiasis and other fungal infections. It also develops SCY-247 to treat systemic fungal diseases. The company has agreements with GlaxoSmithKline, Merck Sharp & Dohme, Hansoh, R-Pharm, and CJSC for ibrexafungerp development. Formerly known as SCYNEXIS Chemistry & Automation, the company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

0.7 USD

Potential

-100%

Strengths

Price to book ratio (0.82) is lower than the sector mean (733.70).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	1.3

SCYNEXIS, Inc.

Overview

Strengths

Weaknesses

Key Financial Data